Laurence Reid
SVP, Chief Business Officer, Alnylam Pharmaceuticals.
Companies
- Metagenomi Therapeutics, Inc.Board member Aug 15, 2025 to now1
- KalVista Pharmaceuticals, Inc.Board member Nov 26, 2024 to now2
- Decibel Therapeutics, Inc.Board member Feb 11, 2021 to Sep 25, 20233
- Decibel Therapeutics, Inc.Officer Feb 11, 2021 to Sep 25, 20233
- Decibel Therapeutics, Inc.Chief executive officer Sep 17, 2021 to Sep 17, 20214
- Decibel Therapeutics, Inc.President Sep 17, 2021 to Sep 17, 20214
- Alnylam PharmaceuticalsSVP, Chief Business Officer Jun 3, 2010 to Jan 5, 20155
Holdings
Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.
Shares held
- Metagenomi Therapeutics, Inc. MGX20,000 shares6$16.3K at $0.81Sep 9, 2026
- Decibel Therapeutics, Inc.0 shares7Sep 25, 2023
As of each latest filing. The line shows shares held over time.
Recent filings
- Sep 9, 2026Bought 117 shares at $1.18 of Metagenomi Therapeutics, Inc.6
- Sep 9, 2026Bought 19,883 shares at $1.17 of Metagenomi Therapeutics, Inc.6
- Sep 25, 2023Returned to company 220,849 shares of Decibel Therapeutics, Inc.7
- Mar 16, 2023Granted 195,000 shares of Decibel Therapeutics, Inc.8
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8SEC EDGARForm 4 filed Mar 17, 2023